Thor Medical ASA (OSL:TRMED) Interest Expense: kr-0.60 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:TRMED Thor Medical ASA OSL:TRMED
26 GF Score
Price kr4.39
! 2 Warning Signs
View Full Analysis

What is Thor Medical ASA Interest Expense?

Thor Medical ASA OSL:TRMED +1.15% 26 Interest Expense is kr-0.60 Mil as of Dec. 2025. GuruFocus rates OSL:TRMED with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Thor Medical ASA's interest expense for the six months ended in Dec. 2025 was kr -0.40 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.60 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Thor Medical ASA's Operating Income for the six months ended in Dec. 2025 was kr -36.40 Mil. Thor Medical ASA's Interest Expense for the six months ended in Dec. 2025 was kr -0.40 Mil. Thor Medical ASA did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Thor Medical ASA  (OSL:TRMED) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Thor Medical ASA's Interest Expense for the six months ended in Dec. 2025 was kr-0.40 Mil. Its Operating Income for the six months ended in Dec. 2025 was kr-36.40 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was kr159.20 Mil.

Thor Medical ASA's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Thor Medical ASA did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Thor Medical ASA Interest Expense Historical Data

* Premium members only.

The historical data trend for Thor Medical ASA's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thor Medical ASA Interest Expense Chart

Thor Medical ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.41 0.00 -0.17 -0.10 -0.60

Thor Medical ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.10 -0.10 -0.20 -0.40
OSL:TRMED
26GF Score
Thor Medical ASA OSL:TRMED
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thor Medical ASA Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-0.60 Mil mean?
Thor Medical ASA (OSL:TRMED) has a Interest Expense of kr-0.60 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Thor Medical ASA and its competitors.
Is Thor Medical ASA's Interest Expense too high?
Thor Medical ASA's current Interest Expense is kr-0.60 Mil. Overall, Thor Medical ASA has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's Interest Expense compare to VRTX and REGN?
Thor Medical ASA's Interest Expense of kr-0.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Thor Medical ASA and its competitors. Thor Medical ASA's current Interest Expense is kr-0.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (OSL:TRMED) has a current Interest Expense of kr-0.60 Mil. The current Interest Expense is kr-0.60 Mil. Thor Medical ASA's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Thor Medical ASA (OSL:TRMED), the current Interest Expense is kr-0.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thor Medical ASA Business Description

Other Exchanges 0R6Y:UK8NN:Germany
Address Drammensveien 167, Oslo, NOR, 0277
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
26GF Score

Get the complete analysis for OSL:TRMED

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.39
Price